Nurix director receives 31,250-share option grant
Nurix Therapeutics director Anil Kapur received a stock option grant covering 31,250 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nurix Therapeutics director Anil Kapur received a stock option grant covering 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. This is a compensation-related award, not an open-market purchase.
The option vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as Kapur continues providing service to Nurix through the vesting date. After this grant, his directly held option position from this award totals 31,250 underlying shares.
Insider Trade Summary
Grant/Award: 31,250 shares
Grant/Award
1 txn
Insider
Kapur Anil
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (right to buy) | 31,250 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (right to buy) — 31,250 contracts (Direct)
Footnotes (1)
- F1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Key Figures
Option grant size: 31,250 shares
Exercise price: $15.86 per share
Post-grant option holdings from award: 31,250 options
+2 more
5 metrics
Option grant size
31,250 shares
Director stock option underlying common shares
Exercise price
$15.86 per share
Stock option exercise price for the grant
Post-grant option holdings from award
31,250 options
Total shares underlying this option after transaction
Option expiration date
May 14, 2036
Expiration of director stock option grant
Vesting deadline
May 15, 2027
Latest possible full vesting date if service continues
Key Terms
Director Stock Option, exercise price, vesting, expiration date, +1 more
5 terms
Director Stock Option financial
"Director Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price": "15.8600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option vests as to 100% of the award"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date": "2036-05-14T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Nurix Therapeutics (NRIX) director Anil Kapur report in this Form 4?
Director Anil Kapur reported receiving a stock option grant for 31,250 shares of Nurix common stock. The award is compensation-related, not an open-market purchase, and gives him the right to buy shares at a fixed exercise price in the future.
How large is Anil Kapur’s new stock option grant at Nurix Therapeutics (NRIX)?
Anil Kapur was granted options over 31,250 shares of Nurix common stock. These options represent a new derivative position and give him the right to buy that many shares once vested, at a fixed exercise price set in the award.
What is the exercise price of Anil Kapur’s Nurix (NRIX) stock options?
The stock options granted to Anil Kapur have an exercise price of $15.86 per share. This means he can purchase Nurix common shares at $15.86 once the options vest and before they expire, regardless of the future market price.
When do Anil Kapur’s Nurix Therapeutics (NRIX) stock options vest?
The options vest 100% on the earlier of Nurix’s next annual stockholder meeting or May 15, 2027. Vesting is conditioned on Kapur continuing to provide service to the company through the applicable vesting date, as specified in the footnote.
When do Anil Kapur’s Nurix (NRIX) stock options expire?
The stock options granted to Anil Kapur expire on May 14, 2036. After that expiration date, any unexercised portion of the 31,250-share option award will no longer be exercisable, so the right to buy shares under this grant will lapse.
Is Anil Kapur’s Nurix (NRIX) Form 4 transaction a market purchase or sale?
The Form 4 reflects a grant or award acquisition, not a market trade. The transaction code is “A,” indicating a compensatory stock option grant. No open-market buying or selling of Nurix common stock is reported in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
